Skip to content Skip to primary navigation
Contact us
News

Glob­al Bioen­er­gies – Cap­it­al increase a great success

15.07.2013
Evry (France) — Glob­al Bioen­er­gies — NYSE Altern­ext Par­is: FR0011052257 ALGBE — an indus­tri­al bio­logy com­pany devel­op­ing light olefin biopro­duc­tion pro­cesses, announces hav­ing suc­cess­fully closed its cap­it­al increase launched June 27th 2013. The cap­it­al increase launched on June 27th by Glob­al Bioen­er­gies has been a great suc­cess with a total order for 1.15 mil­lion ordin­ary shares amount­ing to approx­im­ately 28.6 mil­lion euros and rep­res­ent­ing a sub­scrip­tion rate of 143%.

The Com­pany’s Chief Exec­ut­ive Officer has decided to fully exer­cise the exten­sion clause. The oper­a­tion’s final gross value there­fore amounts to 23 mil­lion euros and res­ults in the cre­ation of 927,419 new shares.

Lili­ane Bron­stein, Glob­al Bioen­er­gies’ Chief Fin­an­cial Officer points out: ​“The French invest­ment funds have largely par­ti­cip­ated in this oper­a­tion. We have also attrac­ted investors from sev­er­al oth­er European coun­tries as well as from the USA. Over­all, orders have been placed by about forty insti­tu­tion­al investors.“

Karine Lignel, Dir­ect­or of Par­ti­cip­a­tions at CM-CIC Cap­it­al Innov­a­tion spe­cifies: ​“CM-CIC Cap­it­al Innov­a­tion has been attrac­ted both by the already out of the lab, highly innov­at­ive tech­no­logy and by the com­pany’s busi­ness mod­el, based on out licens­ing to large indus­tri­al com­pan­ies. It is a very good time for us to take part, upon launch­ing of the indus­tri­al pilot phase, and in the indus­tri­al bio­logy sec­tor which we see as stra­tegic.”

Alain Com­mis­saire, Chief Exec­ut­ive Officer of Cristal Uni­on adds: ​“Cristal Uni­on has decided to rein­force its par­ti­cip­a­tion in Glob­al Bioen­er­gies’ cap­it­al to accom­pany Glob­al Bioen­er­gies’ indus­tri­al devel­op­ment and to strengthen our group’s involve­ment in the prom­ising field of bio­sourced chem­istry.“

Marc Del­court, Glob­al Bioen­er­gies’ Chief Exec­ut­ive Officer con­cludes: ​“Indi­vidu­als’ sub­scrip­tions amount to 2.3 mil­lion euros, a major suc­cess in today’s fin­an­cial envir­on­ment. The pro­ceeds will enable us to pro­pel Glob­al Bioen­er­gies into a new phase, largely ded­ic­ated to indus­tri­al devel­op­ment”.

Set­tle­ment-deliv­ery of the new shares will take place on July 16th2013. The new shares will bear all rights and will be entirely fun­gible with exist­ing shares cur­rently traded on NYSE Altern­ext Par­is. Admis­sion of the new shares to trad­ing is also sched­uled for July16th2013 on the same quo­ta­tion line as exist­ing shares.

Use of the pro­ceeds from the cap­it­al increase will include:

  • The fin­an­cing of the isob­utene pro­cess’ indus­tri­al­iz­a­tion phase via the con­struc­tion of two pilots.
  • The devel­op­ment of the butadiene and pro­pyl­ene processes.
  • The ini­ti­ation of new programs.

About GLOB­AL BIOENERGIES

Glob­al Bioen­er­gies is one of the few com­pan­ies world­wide, and the only one in Europe, that is devel­op­ing a pro­cess to con­vert renew­able resources into hydro­car­bons through fer­ment­a­tion. The Com­pany ini­tially focused its efforts on the pro­duc­tion of isob­utene, one of the most import­ant pet­ro­chem­ic­al build­ing blocks that can be con­ver­ted into fuels, plastics, organ­ic glass and elast­omers. Glob­al Bioen­er­gies con­tin­ues to improve the yield of its pro­cess and pre­pares the phase ded­ic­ated to indus­tri­al pilot test­ing. The com­pany recently rep­lic­ated this suc­cess to pro­pyl­ene and butadiene and is also look­ing to con­tin­ue with oth­er mem­bers of the gaseous olefins fam­ily, key molecules at the heart of pet­ro­chem­ic­al industry. Glob­al Bioen­er­gies is lis­ted on NYSE Altern­ext Par­is (FR0011052257 — ALGBE).
Source: Glob­al Bioenergies 
All news